Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ligand PharmaceuticalsSTU:LGDN 74 EV-to-FCF is 50.61 as of Aug. 06, 2026, which is 121% above its 10-year median of 22.91. GuruFocus rates STU:LGDN with a GF Score™ of 74/100 and a GF Value™ of €153.80 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 343 Biotechnology companies, Ligand Pharmaceuticals ranks worse than 79.59% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ligand Pharmaceuticals's Enterprise Value is €4,963.9 Mil.
Ligand Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €98.1 Mil. Therefore, Ligand Pharmaceuticals's EV-to-FCF for today is 50.61.
The historical rank and industry rank for Ligand Pharmaceuticals's EV-to-FCF or its related term are showing as below:
STU:LGDN'
s EV-to-FCF Range Over the Past 10 Years
Min: -287.21 Med: 22.91 Max: 299.51
Current: 50.22
During the past 13 years, the highest EV-to-FCF of Ligand Pharmaceuticals was 299.51. The lowest was -287.21. And the median was 22.91.
STU:LGDN's EV-to-FCF is ranked worse than 79.59% of 343
companies
in the Biotechnology industry
Industry Median: 14.62
vs STU:LGDN: 50.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ligand Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Ligand Pharmaceuticals's share price for today is €260.00.
Ligand Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.069.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LGDN vs CGON, DFTX, XENE: EV-to-FCF Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's EV-to-FCF falls into.
Ligand Pharmaceuticals's current Enterprise Value is €4,963.9 Mil.
Ligand Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €98.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (STU:LGDN) has a EV-to-FCF of 50.61 as of Aug. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ligand Pharmaceuticals and its competitors. This is 121% above median its historical median of 22.91. According to the industry distribution chart, Ligand Pharmaceuticals ranks #273 out of 343 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Ligand Pharmaceuticals' EV-to-FCF too high?
Ligand Pharmaceuticals' current EV-to-FCF of 50.61 is 121% above median its 10-year median of 22.91. The Biotechnology industry median EV-to-FCF is 14.62. Ligand Pharmaceuticals' value of 50.61 is 246.2% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #273 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' EV-to-FCF compare to CGON and DFTX?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #273 out of 343 companies for EV-to-FCF. This places Ligand Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.62. Ligand Pharmaceuticals' value of 50.61 is 246.2% above this benchmark. While the company's 10-year median is 22.91 vs. the industry median of 14.62, Ligand Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.62, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current EV-to-FCF of 50.61 is 246.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ligand Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current EV-to-FCF is 50.61, which is 121% above median its own 10-year median of 22.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (STU:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €153.80, compared to a current price of €260.00 — trading 69.1% above its estimated fair value. The current EV-to-FCF is 50.61, which is 121% above median its 10-year median of 22.91 and 246.2% above the Biotechnology industry median of 14.62. Ligand Pharmaceuticals' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ligand Pharmaceuticals (STU:LGDN), the current EV-to-FCF is 50.61 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (STU:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €260.00 is trading 69.1% above its estimated GF Value™ of €153.80.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:LGDN:
EV-to-FCF: 50.61 (121% above median its 10-year median of 22.91)
GF Value™: €153.80 vs. price of €260.00 (69.1% above fair value)
Industry Position: 246.2% above the Biotechnology median (#273 of 343)
No single metric tells the full story. See the STU:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
74GF Score
Get the complete analysis for STU:LGDN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LGDN has been successfully added to your 
